Considering that HDAC6 is involved in multiple cancer-related pathways and that there was no severe toxicity with HDAC6 inhibition in animal models [154], some therapeutic advantages have been postulated for selective therapeutic targeting of HDAC6. The gene discussed is HDAC6; the disease is cancer.